MitoQ to Improve Vascular Funciton in Preeclampsia

Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.

NCT Number	NCT07229261
Lead Sponsor	Medical College of Wisconsin Collaborators: Bill and Melinda Gates Foundation
Conditions	Preeclampsia, Pregnancy
Enrollment	80 participants
Start Date	2026-03-18
Primary Completion	2027-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-01